AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Lmcg Investments LLC

Lmcg Investments LLC lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 41.7% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 23,514 shares of the company’s stock after selling 16,845 shares during the period. Lmcg Investments LLC’s holdings in AstraZeneca were worth $1,541,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in AZN. Stratos Wealth Advisors LLC boosted its position in shares of AstraZeneca by 2.0% in the 3rd quarter. Stratos Wealth Advisors LLC now owns 6,699 shares of the company’s stock valued at $522,000 after purchasing an additional 133 shares during the period. Crumly & Associates Inc. lifted its stake in AstraZeneca by 2.2% in the third quarter. Crumly & Associates Inc. now owns 6,644 shares of the company’s stock valued at $518,000 after buying an additional 143 shares during the last quarter. Diversify Wealth Management LLC boosted its holdings in shares of AstraZeneca by 3.6% in the fourth quarter. Diversify Wealth Management LLC now owns 4,402 shares of the company’s stock valued at $295,000 after acquiring an additional 153 shares during the period. Veery Capital LLC grew its position in shares of AstraZeneca by 4.7% during the fourth quarter. Veery Capital LLC now owns 3,503 shares of the company’s stock worth $230,000 after acquiring an additional 157 shares during the last quarter. Finally, Harbour Investments Inc. increased its holdings in shares of AstraZeneca by 1.9% in the 3rd quarter. Harbour Investments Inc. now owns 8,805 shares of the company’s stock valued at $686,000 after acquiring an additional 160 shares during the period. Hedge funds and other institutional investors own 20.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a research note on Wednesday, November 6th. UBS Group upgraded shares of AstraZeneca from a “sell” rating to a “neutral” rating in a research note on Wednesday, November 20th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $89.75.

AstraZeneca Stock Up 2.0 %

Shares of AstraZeneca stock opened at $67.96 on Wednesday. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The company has a market cap of $210.75 billion, a P/E ratio of 32.52, a PEG ratio of 1.05 and a beta of 0.46. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.71 and a current ratio of 0.93. The firm has a fifty day moving average of $66.14 and a two-hundred day moving average of $74.39.

AstraZeneca (NASDAQ:AZN) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter last year, the firm earned $0.87 earnings per share. The firm’s revenue was up 18.0% compared to the same quarter last year. On average, analysts forecast that AstraZeneca PLC will post 4.12 earnings per share for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.